LEADING RESEARCH INSTITUTES TO PRESENT NEW DATA USING LUNAPHORE'S COMET™ TECHNOLOGY AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 38th ANNUAL MEETING

MINNEAPOLIS and LAUSANNE, Switzerland, Oct. 25, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Lunaphore, a Bio-Techne brand, will have its technologies featured in several presentations by prominent research centers at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting, taking place in San Diego, November 1-5, 2023. The recent studies will demonstrate the unmatched spatial biology capabilities of the company's universal, end-to-end COMET™ product suite, addressing complex biological questions from various research areas. COMET™ is the only fully automated, high-throughput, hyperplex platform ensuring scalability and reproducibility without the need to conjugate primary antibodies, making panel design much more flexible and faster than any other hyperplex solution.

Lunaphore's sponsored symposia will provide novel insights into the optimization of innovative anti-cancer therapy approaches for head and neck squamous cell carcinoma (HNSCC). Researchers from the collaborative research project between the Earle A. Chiles Research Institute a division of Providence Cancer Institute, and Lunaphore will present the results of a hyperplex-based characterization of the tumor microenvironment (TME) in response to combined immunotherapy and stereotactic ablative radiation therapy (iSABR) neoadjuvant treatment of HNSCC, facilitated by the COMET™ platform. The presentation will discuss strategies for rapid hyperplex sequential immunofluorescence (seqIF™) panel development and optimization, as well as methodologies for high-throughput data analytics. The novel seqIF™ method allows an unprecedented analysis of the immune compartment and potentially increases the clinical success of such therapies.

Additionally, poster presentations will highlight how research institutes use their off-the-shelf antibodies on COMET™ to map immune and tumoral cells in lymphomas and various cancer tissues with the seqIF™ approach. Furthermore, a poster of industry partnership will demonstrate proof-of-concept COMET™ workflow for same-slide, fully automated multiomics analysis of the TME.

Lunaphore's scientists will be available at booth #530 to provide live demonstrations of the COMET™ system and access to raw staining images of various cancer types.

Sponsored symposia details

Using hyperplex immunofluorescence to characterize the immune response to iSABR in head and neck cancer

Location: room 15AB 

Date & Time:  November 3, 2023 | 12:15 - 1:15 PM EST

Speakers:

• Dr. Brian Piening, Earle A. Chiles Research Institute a division of Providence Cancer Institute, USA
• Dr. Rom Leidner, Earle A. Chiles Research Institute a division of Providence Cancer Institute, USA
• Dr. Marco Cassano, Lunaphore – a Bio-Techne brand, Switzerland

The symposia will take place during the lunch break. Lunaphore will provide lunch for the attendees.

Poster presentation details

Development and optimization of a broad hyperplex immunofluorescence assay for tumor immune microenvironment characterization
Poster number: 65
Date & Time:  November 3, 2023 | 12:15 - 1:15 PM | 5:10 – 6:40 PM EST
Presenter: Racheli Ben-Shimol, B.Sc., Earle A. Chiles Research Institute a division of Providence Cancer Institute, USA

Automated hyperplex staining and imaging system on various cancer tissues using off-the-shelf antibodies 
Poster number: 222D
Date & Time:  November 4, 2023 | 11:55 AM-1:25 PM | 7:00 – 8:30 PM
Presenter: Ms. Li Yen Chong, Institute of Molecular Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR), Singapore

Immune landscape of adenoid cystic carcinoma using multiplex immunofluorescence and digital pathology
Poster number: 102
Date & Time:  November 4, 2023 | 11:55 AM-1:25 PM
Presenter: Dr. Annie Li, Massachusetts General Hospital and Harvard Medical School, USA

Profiling cytokeratins in the tumor microenvironment using multiplex immunofluorescence
Poster number: 1475
Date & Time:  November 3, 2023 | 12:00 - 1:30 PM | 5:10 – 6:40 PM
Presenter: Danielle Fails, Spatial Biology Manager, Fortis Life Sciences, USA

Adding space to TiME by sequential immunofluorescence: a new dimension for the spatial biomarkers painting in a clinical cohort of lymphoma case
Poster number: 107
Date & Time:  November 3, 2023 | 1:30 PM | 5:10 – 6:40 PM
Presenter: Dr. Pedro Machado Almeida, Lunaphore – a Bio-Techne brand, Switzerland
Research conducted in collaboration with École Polytechnique Fédérale de Lausanne, Swiss Institute for Experimental Cancer Research.

Integration of RNA in situ hybridization and sequential immunofluorescence for same-slide fully automated multi-omics analysis of the tumor microenvironment
Poster number: 71
Date & Time:  November 3, 2023 | 2:00 – 1:30 PM | 5:10 – 6:40 PM
Presenter: Dr. Alice Comberlato, Lunaphore – a Bio-Techne brand, Switzerland
Research conducted in collaboration with ACD – a Bio-Techne brand, USA.

The posters are available during the conference opening times of the given day. Presenters will hold the reception at the given time.

Learn more about the event and book a meeting with Lunaphore here.

To learn more about Lunaphore, please visit: https://lunaphore.com/

About Lunaphore

Lunaphore Technologies S.A. - a Bio-Techne brand, is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore provides solutions based on a game-changing chip technology that can extract spatial proteomic and transcriptomic data from tumors and other tissues, transforming any assay into multiplex spatial biology through a streamlined and easily integrated process. Lunaphore empowers researchers in immunology, immuno-oncology, and neuroscience to push the boundaries of scientific discovery and drug development. Lunaphore's technology enables the identification of biomarker "signatures" with clinical relevance to support the development of diagnostic tools and streamline clinical trials, to ultimately improve patient outcomes. For further information on Lunaphore and its products, please visit https://lunaphore.com.

About COMET™

COMET™ is the only fully automated, high-throughput, hyperplex platform ensuring scalability and reproducibility without the need to conjugate primary antibodies. COMET™ provides walk-away automation, integrating staining, imaging, and image preprocessing steps to obtain standard hyperplex images. COMET™ generates highly robust and reproducible data with full tissue preservation, allowing researchers to perform downstream modalities such as H&E or transcriptomics using the same slide. Its superior tissue profiling capabilities facilitate the analysis of 40 different spatial markers in each automated run on a tissue slide. In contrast to other spatial biology solutions, COMET™ works with off-the-shelf, label-free primary antibodies, making panel design much more flexible and faster than any other hyperplex solution. COMET™ works with regular glass slides from standard histology workflows; it is validated for human and mouse samples and is compatible with any other animal sample. The platform can be used for a wide range of research applications, allowing for a dramatic improvement in the understanding of disease pathology. To learn more about the COMET™ platform, please visit: https://lunaphore.com/products/comet/

About Bio-Techne

Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $1.1 billion in net sales in fiscal 2022 and has approximately 3,000 employees worldwide. For more information on Bio-Techne and its brands, please visit https://www.bio-techne.com or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube.

About Providence Cancer Institute of Oregon

Providence Cancer Institute is a leading provider of cancer care in Oregon and a global leader in immuno-oncology. We offer the latest in cancer services, including diagnostic, treatment, prevention, education, support and internationally renowned research. Through our Earle A. Chiles Research Institute, a world-class cancer research facility located within the Robert W. Franz Cancer Center, investigators lead more than 400 active clinical trials in key areas such as cancers of the breast, colon, prostate, lung, esophagus, liver and pancreas, head and neck, ovary, skin and blood. Learn more at Providence.org/ORcancer.

For further information on Lunaphore contact:

Lindsey Roger
Lunaphore Corporate Communications
Email: [email protected]

Bio-Techne Corporation (NASDAQ: TECH)
Contact: David Clair, Vice President, Investor Relations & Corporate Development
[email protected] 
612-656-4416

SOURCE Bio-Techne Corporation